Featured Publications
In silico analysis of the immunological landscape of pituitary adenomas
Yeung JT, Vesely MD, Miyagishima DF. In silico analysis of the immunological landscape of pituitary adenomas. Journal Of Neuro-Oncology 2020, 147: 595-598. PMID: 32236778, PMCID: PMC7261241, DOI: 10.1007/s11060-020-03476-x.Peer-Reviewed Original ResearchConceptsPituitary adenomasImmunological landscapeImmune cellsM2 macrophagesPituitary tumorsAdenoma subtypesSilent pituitary tumorsMemory T cellsImmune cell typesDifferent immunotherapiesHigh CD8Immune infiltratesImmune landscapeSilent tumorsGH tumorsImmunological compositionMacrophage fractionT cellsMast cellsTumor subtypesSolid tumorsSubclinical casesAdenomasTumorsSubtypes
2021
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Yeung J, Yaghoobi V, Miyagishima D, Vesely MD, Zhang T, Badri T, Nassar A, Han X, Sanmamed MF, Youngblood M, Peyre M, Kalamarides M, Rimm DL, Gunel M, Chen L. Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. Neuro-Oncology 2021, 23: 1922-1935. PMID: 33914067, PMCID: PMC8563319, DOI: 10.1093/neuonc/noab075.Peer-Reviewed Original ResearchConceptsColony-stimulating factor-1Myeloid cellsMalignant meningiomasTumor microenvironmentCSF1/CSF1RRNA-seqRNA sequencingHuman meningiomasImmune subsetsGene expressionT cellsTreatment strategiesNormalization cancer immunotherapyImportant regulatorCell typesNovel immunocompetent murine modelDeath ligand 1 (PD-L1) expressionCell death receptor-1Immunosuppressive myeloid cellsDeath receptor-1Ligand 1 expressionFactor 1Immune cell typesImmunocompetent murine modelEffective treatment strategies